Oncology: Pierre Fabre unveils an innovative plan to improve patients' quality of life

Paris, December 17, 2025 – In collaboration with a council of European opinion leaders, Pierre Fabre Laboratories announces a major initiative aimed at transforming the management and prevention of adverse skin effects associated with oncology treatments. This ambitious project, an integral part of the Act for Skin, Care for Cancer Patients program, will enable comprehensive and harmonized care for cancer patients through the drafting of a multidisciplinary consensus.

Consensus guidelines for the prevention of dermatological toxicities

Last October, a pioneering article, "From supportive care to strategic intervention: toward a multidisciplinary approach to cutaneous adverse events in cancer treatment," was published in the journal Supportive Care in Cancer, a recognized publication in the field of oncology.
This letter to the editor highlights the importance of addressing unmet needs in oncology in order to better manage the adverse skin effects in cancer patients, thereby improving their care and quality of life, which is significantly impacted.
This project, which brings together oncologists, dermatologists, pharmacists and patient associations, aims to draft recommendations applicable to all patients, with specific advice depending on the treatment.

This article marks a key milestone in our Act For Skin, Care for Cancer Patients program. Through this initiative, Pierre Fabre Laboratories is committed to establishing an essential link between healthcare professionals and patients themselves in order to offer unique care solutions that encompass prevention, treatment and patient support.

Núria Perez Cullell

Head of Medical and Patient Consumer Department at Pierre Fabre

These figures highlight the significant negative impact of adverse skin reactions.

Although oncology treatments have evolved considerably in recent years, moving from traditional chemotherapy to more targeted and immunological approaches, they are often accompanied by adverse skin reactions that can seriously impact patients' quality of life.

According to a survey conducted in France* on 293 patients:
•    99% of patients surveyed experienced these skin toxicities,
•    59% declared that it affected their daily lives,
•    93% of patients indicated that the skincare products they used before treatment were no longer suitable afterward, requiring a change in their skincare routine.
Given these figures, it is imperative to develop effective and consistent management strategies.

The three priority objectives of this multidisciplinary consensus

1. Develop multidisciplinary recommendations:
The main objective is to create multidisciplinary consensus recommendations for the prevention of dermatological toxicities in cancer patients. These include general recommendations and treatment-specific guidelines to improve patient care and quality of life.

2. Strengthen training for patients and caregivers:
It is crucial to train oncologists, patients and caregivers to recognize the warning signs and symptoms that require a dermatological consultation. This training aims to empower patients to effectively manage skin toxicities and seek medical advice in a timely manner.

3. Integrating artificial intelligence (AI) into care:
This article highlights the potential role of AI in managing the side effects associated with cancer treatments. AI can help predict which patients are more likely to develop specific adverse effects, personalize treatments and monitor skin toxicities.

A leading European expert advisory board

The Act for Skin, Care for Cancer Patients project is supported by an advisory board composed of key opinion leaders, including:
•    Dr. Davide Fattore (Italy): Expert in oncodermatology at the University of Naples Federico II.
•    Dr. Michela Valeria Starace (Italy): Specialist in oncodermatology at IRCCS Azienda Ospedaliero-Universitaria Di Bologna.
•    Dr. Laura Serra-García (Spain): Dermatologist at Hospital Clínic de Barcelona.
•    Dr. Antonin Schmitt (France): Pharmacist at INSERM U1231, Dijon.
•    Dr. Florian Scotté (France): Oncologist, Head of the Interdisciplinary Department of Patient Care Organization, Gustave Roussy Institute.
•    "Patients en réseau" association represented by Ms. Guéroult Accolas

Skin reactions to cancer treatments can no longer be overlooked. Thanks to our multidisciplinary approach, we hope to offer patients a better quality of life.

Pr Davide Fattore

About Act For Skin, Care for Cancer Patients

Act For Skin, Care for Cancer Patients is a unifying and mobilizing initiative by Pierre Fabre Laboratories designed to meet the needs of healthcare professionals - from nurses to oncologists to pharmacists - and cancer patients, who often suffer from acute skin reactions during their treatment. This unique program is based on the development of effective and safe healthcare solutions, while aiming for a holistic approach that encompasses prevention, treatment, and patient support during and after treatment.

To find out more, click here : From supportive care to strategic intervention: toward a multidisciplinary approach to cutaneous adverse events in cancer treatment - PubMed

ABOUT PIERRE FABRE LABORATORIES

*Skin reactions to cancer treatments can no longer be overlooked. Thanks to our multidisciplinary approach, we hope to offer patients a better quality of life," says Dr. Davide Fattore.
*Chabanol H, Guéroult-Accolas L (2023) Impact of skin side effects on patients' daily lives: their point of view. 27 September 2023. Available from: https:// www. patientsen reseau. fr/ wp- conte nt/ uploa ds/ 2023/ 09/ POSTE RTOXCUTANE
ESAFS OS. pdf. Accessed 31 March 2025

Press Contact

Caroline Perdrix Thomas
caroline.perdrix@pierre-fabre.com